|
|
|
| Effect of Tiotropium Bromide combined with Budesonide on immune function and pulmonary ventilation function in patients with asthma -chronic obstructive pulmonary disease overlap syndrome |
| SU Wei |
| Department of Respiratory Medicine, Shangrao Municipal Hospital, Jiangxi Province, Shangrao 334000, China |
|
|
|
|
Abstract Objective To explore the effect of Tiotropium Bromide combined with Budesonide on immune function and pulmonary ventilation function in patients with asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS).Methods A total of 94 patients with ACOS admitted to Shangrao Municipal Hospital between January 2019 and January 2020 were selected as the research subjects, and they were divided into the control group and the observation group according to the random number table method, with 47 cases in each group.The control group was treated with Budesonide Inhalation, and the observation group was treated with Tiotropium Bromide combined with Budesonide Inhalation.The clinical effect, pulmonary function, immune function indexes and total incidence of adverse reactions before and after treatment were compared between the two groups.Results The total effective rate of observation group was higher than that of control group, and the difference was statistically significant (P<0.05).After treatment, the forced expiratory volume in the first second (FEV1), the ratio of forced expiratory volume in the first second to forced vital capacity (FEV1/FVC), forced vital capacity (FVC) and inspiratory fraction (IC/TLC) in the observation group were higher than those in the control group, and the differences were statistically significant (P<0.05).After treatment, the levels of helper T cell type 1 (Th1), helper T cell type 2 (Th2) and Th1/Th2 in the two groups were higher than those before treatment, and the observation group was higher than of the control group, the differences were statistically significant (P<0.05).There was no statistically significant difference in the total incidence of adverse reactions between the two groups (P>0.05).Conclusion The combined application of Tiotropium Bromide and Budesonide in the treatment of patients with ACOS can effectively improve the pulmonary function and immune function, enhance the efficacy of clinical treatment and reduce the occurrence of adverse reactions.
|
|
|
|
|
|
| [1] |
张勇，韩兆勇.孟鲁司特钠片联合沙美特罗替卡松粉吸入剂治疗哮喘-慢性阻塞性肺疾病重叠综合征的临床研究[J].中国临床药理学杂志，2020，36（7）：744-746.
|
| [2] |
丁丽丽.多学科合作护理模式对哮喘-慢性阻塞性肺疾病重叠综合征患者的影响[J].中国实用护理杂志，2020，36（21）：1618-1622.
|
| [3] |
崔丽平，陈希胜，李旭.布地奈德粉吸入剂联合噻托溴铵粉雾剂治疗哮喘-慢阻肺重叠综合征的临床疗效[J].实用心脑肺血管病杂志，2017，25（3）：100-103.
|
| [4] |
李瑞敏，徐伟涵，金建敏，等.哮喘-慢性阻塞性肺疾病重叠综合征临床诊断的初步探讨[J].中国呼吸与危重监护杂志，2018，17（6）：557-560.
|
| [5] |
李明，李林旭，王朔，等.噻托溴铵与异丙托溴铵治疗哮喘-慢阻肺重叠综合征效果及对血清TNF-α、IL-6 影响的比较[J].疑难病杂志，2017，16（7）：673-677.
|
| [6] |
李洪晓，吴细英.老年哮喘-慢性阻塞性肺疾病重叠综合征临床特征及危险因素[J].中国老年学杂志，2019，39（21）：5264-5266.
|
| [7] |
李竹英，邸宁，何俊杰.中西医对于哮喘-慢性阻塞性肺疾病重叠综合征的认识、诊断及治疗的研究进展[J].时珍国医国药，2017，28（8）：1985-1987.
|
| [8] |
Hancox RJ，Zhang X.Early life origins of the Asthma-COPD Overlap Syndrome?[J].Respirology，2018，23（8）：731-732.
|
| [9] |
王宁，栗娜，韩巧玲，等.布地奈德福莫特罗联合噻托溴铵治疗哮喘-慢性阻塞性肺疾病重叠的临床研究[J].中国综合临床，2021，37（1）：39-45.
|
| [10] |
李斯南，朱述阳，罗涛，等.吸入激素联合噻托溴铵治疗哮喘-慢性阻塞性肺疾病重叠综合征的效果及对血清炎症因子水平的影响[J].临床和实验医学杂志，2019，18（16）：1748-1751.
|
| [11] |
王秀丽，赵岩，刘萍，等.布地奈德对感染诱发哮喘急性发作患儿趋化素样因子-1 水平及免疫功能的影响[J].中国儿童保健杂志，2020，28（1）：100-103.
|
| [12] |
赵润杨，孟泳，王东，等.补肺活血胶囊联合布地奈德对AECOPD 合并肺部感染的治疗效果[J].中华医院感染学杂志，2020，30（9）：1345-1349.
|
| [13] |
梁文晋，关键.噻托溴铵联合沙美特罗替卡松治疗老年慢性阻塞性肺疾病患者的临床效果[J].中国老年学杂志，2020，40（7）：1427-1430.
|
| [14] |
蔡仁萍，潘倩倩，孙培欣，等.噻托溴铵联合肺康复治疗轻中度支气管扩张症的疗效[J].中国呼吸与危重监护杂志，2020，19（4）：403-406.
|
| [15] |
方佳，肖翔，李瑞金，等.噻托溴铵联合福莫特罗/布地奈德治疗哮喘-慢性阻塞性肺疾病重叠综合征的疗效分析[J].临床内科杂志，2018，35（3）：203-204.
|
| [16] |
邱伟群，陈东锋，许为钊，等.孟鲁司特结合普米克令舒对哮喘患者疗效、肺功能及T 淋巴细胞亚群的影响研究[J].中国医药科学，2020，10（6）：66-68.
|
|
|
|
